Pharmacological and nonpharmacological methods for rate control

Canadian Journal of Cardiology

Volumn 21, Issue SUPPL. B, 2005, Pages

  Dorian, Paul ^a,c   Connors, Sean P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Atrial fibrillation; Atrial fibrillation therapy; Ventricular rate control

Indexed keywords

AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; METOPROLOL; PLACEBO; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; ELECTROCARDIOGRAPHY; EXERCISE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART RATE; HUMAN; MONOTHERAPY; SUSTAINED RELEASE PREPARATION;

ATRIAL FIBRILLATION; HEART RATE; HUMANS; PRACTICE GUIDELINES;

EID: 33748591972     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789-94.
2. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
3. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: Strategies to control, combat, and cure. Lancet 2002;359:593-603.
4. Verma A, Newman D, Geist M, et al. Effects of rhythm regularization and rate control in improving left ventricular function in atrial fibrillation patients undergoing atrioventricular nodal ablation. Can J Cardiol 2001;17:437-45.
5. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1067-78.
6. Levy T, Walker S, Mason M, et al. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: A randomised controlled study. Heart 2001;85:171-8.
7. Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH; Pharmacological Intervention in Atrial Fibrillation (PIAF) Study investigators. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 2003;24:1430-6.
8. Dorian P, Philippon F, Gardner MJ, Talajic M, Sterns L. A randomized pilot study of pacing and ablation vs rate control. Can J Cardiol 2003;19:229A. (Abst)
9. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999;82:170-5.
10. Lang R, Klein HO, Di Segni E, et al. Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind crossover study. Am Heart J 1983;105:820-5.
11. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90.
12. Botto GL, Bonini W, Broffoni T. Modulation of ventricular rate in permanent atrial fibrillation: Randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil. Clin Cardiol 1998;21:837-40.
13. Atwood JE, Myers JN, Sullivan MJ, Forbes SM, Pewen WF, Froelicher VF. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988;93:20-5.
14. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999;33:304-10.
15. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000;49:47-59.
16. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88-90.
17. Koh KK, Song JH, Kwon KS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: Randomized crossover study. Int J Cardiol 1995;52:167-74.
18. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989;13:1-6.
19. Matsuda M, Matsuda Y, Yamagishi T, et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991;25:453-7.
20. Pomfret SM, Beasley CR, Challenor V, Holgate ST. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clin Sci (Lond) 1988;74:351-7.
21. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986;73:316-24.
22. Steinberg JS, Katz RJ, Bren GB, Buff LA, Varghese PJ. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987;9:405-11.
23. DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984;108:1121-7.
24. Zoble RG, Brewington J, Olukotun AY, Gore R. Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. Am J Cardiol 1987;60:39D-45D.
25. Olshansky B, Rosenfeld LE, Warner AL, et al; AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-8.
26. Botker HE, Toft P, Klitgaard NA, Simonsen EE. Influence of physical exercise on serum digoxin concentration and heart rate in patients with atrial fibrillation. Br Heart J 1991;65:337-41.
27. Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of " therapeutic" serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 1975;35:651-5.
28. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J 1990;63:225-7.
29. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-3.
30. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 2000;101:1138-44.
31. Pinter A, Dorian P, Paquette M, et al. Left ventricular performance during acute rate control in atrial fibrillation: The importance of heart rate and agent used. J Cardiovasc Pharmacol Ther 2003;8:17-24.
32. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990;63:157-61.
33. Fuster V, Ryden LE, Asinger RW, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50.
34. Brignole M, Menozzi C, Gasparini M, et al; PAF 2 Study Investigators. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002;23:892-900.
35. Weerasooriya R, Davis M, Powell A, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003;41:1697-702.
36. Ozcan C, Jahangir A, Friedman PA, et al. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 2002;40:105-10.
37. Wilkoff BL, Cook JR, Epstein AE, et al; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288:3115-23.
38. Doshi R, Daoud E, Fellows C, Turk K, Duran A, Hamdan M. PAVE: The first prospective randomized study evaluating BV pacing after ablate and pace therapy. Late Breaking Clinical Trial, ACC Annual Scientific Session, 2004.